Prestige Guides FY27 Sales to $1.28B-$1.29B as Clear Eyes Supply Constraints Weigh
PBH sits 18% above its 52-week low of $42.62.
Summary
Prestige set FY27 revenue guidance at $1.28B-$1.29B and adjusted diluted EPS at $4.48-$4.55, with the outlook reflecting expected lower Clear Eyes availability in the second half. Q2 revenue rose 22.7% to $336.3M from $274.1M, but that growth was acquisition-supported — revenue fell 1.6% excluding foreign currency and $65.1M from acquisitions. Adjusted EPS came in at $1.13 versus $1.07 a year ago, while GAAP net income dropped to $25.3M from $42.2M on acquisition-related costs. H1 adjusted free cash flow slipped to $123.0M from $133.6M. The guidance is the key new piece here: the company did not previously disclose these ranges, and the Clear Eyes supply issue is the swing factor for the second half.
At the time of this announcement, PBH was trading at $50.50 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $42.62 to $71.07. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.